Development, multi-institutional external validation, and algorithmic audit of an artificial intelligence-based Side-specific Extra-Prostatic Extension Risk Assessment tool (SEPERA) for patients undergoing radical prostatectomy: a retrospective cohort studyJethro C.C. Kwong, Alexandre R. Zlotta, Theodorus van der Kwast et al.|The Lancet Digital Health|2023Cited by 16
Treatment of Advanced Renal Cell Carcinoma: Immunotherapies Have Demonstrated Overall Survival Benefits While Targeted Therapies Have NotOtto Hemminki, Akseli Hemminki, Nathan Perlis et al.|European Urology Open Science|2020Cited by 15
Low-volume grade group 2 prostate cancer candidates for active surveillance: a radical prostatectomy retrospective analysisJohan Björklund, Antonio Finelli, Douglas C. Cheung et al.|Scandinavian Journal of Urology|2023Cited by 2
MP61-08 TOWARDS PERSONALIZED CARE OF CT1A PAPILLARY RCC DIAGNOSED ON BIOPSYJohan Björklund, Antonio Finelli, Douglas C. Cheung et al.|The Journal of Urology|2021Cited by 0
MP64-03 LOW METASTATIC POTENTIAL OF COMPLEX RENAL CYSTS: THE Case FOR ACTIVE SURVEILLANCEHannah Thomas, Antonio Finelli, Shideh Abedi et al.|The Journal of Urology|2023Cited by 0